NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $3.22 -0.10 (-3.01%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$3.14 -0.09 (-2.64%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$3.13▼$3.4950-Day Range$2.84▼$3.8052-Week Range$2.77▼$7.18Volume17.81 million shsAverage Volume19.95 million shsMarket Capitalization$1.71 billionP/E RatioN/ADividend YieldN/APrice Target$8.10Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed. At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations. These data feed into proprietary machine-learning pipelines designed to uncover subtle phenotypic changes that traditional screening methods might miss. The company applies this approach to diverse therapeutic areas, including rare genetic diseases, oncology and immunology, with several preclinical programs in its pipeline. Partnerships with pharmaceutical firms and research institutions further extend Recursion’s reach and validate its platform in real-world drug discovery projects. Founded in 2013 by Christopher Gibson and Blake Borgeson, Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, and maintains additional research facilities and corporate offices across North America and Europe. Following its initial public offering in early 2021, the company has continued to expand both its technological capabilities and its therapeutic focus. Led by CEO Christopher Gibson and a management team versed in biology, data science and automation engineering, Recursion is positioned to advance a new paradigm in drug discovery that bridges experimental data with predictive, AI-driven insights.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreRXRX MarketRank™: Recursion Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 488th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $8.10, representing about 151.6% upside from its current price of $3.22.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($0.99) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted33.87% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 8.02.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 55 people have searched for RXRX on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows36 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 414% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $435,942.00 in company stock.Percentage Held by Insiders8.43% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesRecursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9 at 3:03 PM | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) and Protara Therapeutics (NASDAQ:TARA) Head to Head SurveyJune 8 at 3:49 AM | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.June 10 at 1:00 AM | Brownstone Research (Ad)Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 23,588 Shares of StockJune 6, 2026 | insidertrades.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 4,386 Shares of StockJune 5, 2026 | insidertrades.comRecursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business UpdatesJune 4, 2026 | finance.yahoo.comWhy Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsJune 4, 2026 | finance.yahoo.comRecursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationJune 4, 2026 | finance.yahoo.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $4.09 at the beginning of 2026. Since then, RXRX stock has decreased by 21.3% and is now trading at $3.22. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm's quarterly revenue was down 56.8% compared to the same quarter last year. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $412 million in an IPO on Thursday, April 15th 2021. The company issued 24,242,424 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Recursion Pharmaceuticals' top institutional investors include Sumitomo Mitsui Trust Group Inc. (1.03%), Amova Asset Management Americas Inc. (1.03%), First Trust Advisors LP (0.49%) and Bank of America Corp DE (0.47%). Insiders that own company stock include Blake Borgeson, Najat Khan, Michael Secora, Ben R Taylor, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Shafique Virani, Terry-Ann Burrell, Zavain Dar and Namandje Bumpus. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/06/2026Today6/10/2026AGM 20266/17/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 RXRX's financial health is in the Red zone, according to TradeSmith. RXRX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees400Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$8.10 High Price Target$11.00 Low Price Target$5.50 Potential Upside/Downside+151.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.76 million Net Margins-842.95% Pretax Margin-849.85% Return on Equity-54.33% Return on Assets-40.60% Debt Debt-to-Equity Ratio0.01 Current Ratio5.47 Quick Ratio5.47 Sales & Book Value Annual Sales$74.68 million Price / Sales22.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book1.50Miscellaneous Outstanding Shares529,910,000Free Float485,234,000Market Cap$1.71 billion OptionableOptionable Beta1.04 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RXRX) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
